Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates China-based CanSino Biologics has received regulatory approval to conduct Phase I clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) candidate.
The candidate is being developed in alliance with Beijing Institute of Biotechnology (BIB), based on the viral vector vaccine technology platform previously used to develop Ebola vaccine.
In preclinical animal studies of Ad5-nCoV, the vaccine candidate was able to trigger a strong immune response and a satisfactory safety profile.
CanSino chairman and CEO Xuefeng Yu said: “Having committed to provide unconditional support to fight against the global epidemic, CanSinoBIO is determined